期刊文献+

维格列汀及阿卡波糖对老年糖尿病患者不良反应发生率及血糖水平的影响 被引量:6

Effects of vildagliptin and acarbose on the incidence of adverse reactions and blood glucose levels in elderly diabetic patients
下载PDF
导出
摘要 目的探讨维格列汀及阿卡波糖对老年糖尿病患者不良反应发生率及血糖水平的影响。方法 100例老年糖尿病患者,随机分为对照组和观察组,各50例。对照组患者采用阿卡波糖进行治疗,观察组患者采用维格列汀进行治疗,对比两组患者的治疗效果、不良反应发生率及治疗前后的血糖水平。结果治疗后,对照组患者的治疗总有效率为80.00%,观察组患者的总有效率为94.00%;观察组患者的治疗总有效率明显高于对照组,差异有统计学意义(P<0.05)。观察组患者反胃、腹泻、腹部微痛、腹部不适、头晕头痛、身体乏力发生率均低于对照组,差异有统计学意义(P<0.05)。治疗前两组患者空腹血糖、餐后2 h血糖水平比较差异无统计学意义(P>0.05);治疗后观察组患者空腹血糖、餐后2 h血糖水平低于对照组,差异有统计学意义(P<0.05)。结论采用维格列汀治疗老年糖尿病患者,临床治疗效果较为显著,并且安全性较高,具有临床推广意义。 Objective To discuss the effect of vildagliptin and acarbose on the incidence of adverse reactions and blood glucose levels in elderly diabetic patients. Methods A total of 100 elderly diabetic patients were randomly divided into control group and observation group, with 50 cases in each group. The control group was treated with acarbose, and the observation group was treated with vildagliptin. Comparison were made on treatment effect, incidence of adverse reactions and blood glucose levels before and after treatment between the two groups. Results After treatment, the control group had total treatment effective rate as 80.00%, which was 94.00% in the observation group. The observation group had obviously higher total treatment effective rate than the control group, and the difference was statistically significant(P〈0.05). The observation group had lower incidence of nausea, diarrhea, slight abdominal pain, abdominal discomfort, dizziness, headache and physical weakness than the control group, and their difference was statistically significant(P〈0.05). Before treatment, both groups had no statistically significant difference in fasting blood glucose, 2 h postprandial blood glucose levels(P〉0.05). After treatment, the observation group had lower fasting blood glucose and 2 h postprandial blood glucose levels than the control group, and their difference was statistically significant(P〈0.05). Conclusion Application of vildagliptin shows remarkable clinical effect in treating elderly diabetic patients with high safety, it contains clinical significance of promotion.
作者 王丽 WANG Li(Department of Internal Medicine, Liaoning Tieling Xifeng County First Hospital, Tiding 112499, China)
出处 《中国实用医药》 2018年第15期103-105,共3页 China Practical Medicine
关键词 维格列汀 阿卡波糖 老年糖尿病 不良反应 血糖 Vildagliptin Acarbose Elderly diabetes Adverse reactions Blood glucose
  • 相关文献

参考文献8

二级参考文献51

  • 1邓斌,戴海斌.维格列汀和阿卡波糖治疗老年糖尿病的临床效果对比评价[J].中国生化药物杂志,2014,34(6):136-138. 被引量:10
  • 2杨彩,郭秀珍,韦艳.胰岛素泵治疗老年2型糖尿病的效果观察[J].第四军医大学学报,2007,28(20):1920-1920. 被引量:2
  • 3Akiko Matsuyama-Yokono,Atsuo Tahara,Ryosuke Nakano,Yuka Someya,Katsuhisa Shiraki,Masahiko Hayakawa,Masayuki Shibasaki.Antidiabetic effects of dipeptidyl peptidase–IV inhibitors and sulfonylureas in streptozotocin-nicotinamide–induced mildly diabetic mice[J].Metabolism.2009(3)
  • 4International Diabetes Federation (IDF). Diabetes Atlas 2013[EB/OL].[ 2014-01-30 ] .http : / / www.eatlas.idf.org / prevalence.
  • 5DEROAS G,MAFFIOLI P. Efficacy and safety profile evaluationof acarbose alone and in association with other antidiabeticdrugs: asystematic review [J].Clin Ther,2012,34(6) : 1221-1236.
  • 6XU W,BI Y,SUN Z,et al. Comparison of the effects on glycaemicontrol andp-cell function in newly diagnosed type 2 diabetespatient of treatment with exenatide, insulin or pioglitazone : amulticentr randomized parallel-group trial (the CONFIDENCEstudy) [J].J Intern Med, 2015,277( 1) : 137-150.
  • 7PONZANI P. Long-term effectiveness and safety of liraglutide inclinical [ J].Minerva Endocrinologica, 2013,38( 1) : 103-112 .
  • 8KIM YG,HAHNS,OH TJ,et al. Differences in the glucose-lowering efficacy of dipcptidyl peptidase-4 inhibitors betweenAsians and non-Asians ; a systematic review and mcta-analysis[J].Diabetologia, 2013,56(4) :696-678.
  • 9LSHIBASHI Y,NISHIN0 Y,MATSUI T,et al. Glucagon-likepeptide-1 suppresses advanced monocyteche-moattra ctantprotein-1 expression in mesangial cells by reducing advancedglycation end product receptor level [J].Metabolism, 2011,60(9):1271-1277.
  • 10SKOV J,DEJGAARD A,FR KI R J,et al. Glucagon-likepeptide-1 (GLP-1) : effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men [J].J ClinEndocrinol Metab,2013,98(4) :E664-E671.

共引文献62

同被引文献19

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部